SOURCE: BioMedReports


July 28, 2011 08:23 ET

Does Medifocus Have the Answer for Increased Shrinkage in Large Breast Cancer Tumors?

LOS ANGELES, CA--(Marketwire - Jul 28, 2011) - In a new Expert Briefing an MIT Researcher and Inventor discusses Medifocus Inc's (PINKSHEETS: MDFZF) (TSX-V: MFS) Minimally Invasive Wide-Field Focused Microwave Thermotherapy in combination with Preoperative Chemotherapy for treatment of breast cancer.

Earlier this month, Medifocus announced that it had initiated its first two clinical sites to begin a randomized Phase III study for the treatment of large breast cancer tumors with focused microwave thermotherapy at the University of Oklahoma Breast Institute in Oklahoma City and at the Comprehensive Breast Center in Coral Springs, Florida.

Now, Alan J. Fenn, PhD, a researcher at Massachusetts Institute of Technology and inventor of the adaptive phased array focused microwave thermotherapy heat treatment for cancer, explains how this ground-breaking treatment technology works. In earlier studies large invasive breast cancer tumors treated with a combination of chemotherapy and two focused microwave heat treatments (approximately 45 degrees Celsius or about 113 degrees Fahrenheit) shrunk nearly 50 percent more (on a relative basis) than tumors treated with chemotherapy alone (88.4% versus 58.8%).

Fenn is the author of two related books, Breast Cancer Treatment by Focused Microwave Thermotherapy (Jones and Bartlett, 2007) and Adaptive Phased Array Thermotherapy for Cancer (Artech 2009).

The full Expert Briefing, including more details about the drug candidate's clinical trial at a major cancer center is available now at:

In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades can go to:

News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com
BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556